AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28434760
Drug: n‐3 polyunsaturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 polyunsaturated fatty acids (PUFA) supplementation at a dosage of 1.28 g/day for 12 weeks
Trial: 21402120
Drug: Mirtazapine (open
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (open label) for 6 weeks after initial treatment
Trial: 20002596
Drug: Placebo (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (initial treatment)
Trial: 23120348
Drug: CT‐RT arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT‐RT arm (neo‐adjuvant chemotherapy with Inj. Cisplatin 100 mg/m(2) on D(1) and Inj 5F.U. 700 mg/m(2) on D(1)‐D(4) at an interval of 21 days, followed by external radiation)
Trial: 26265197
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac epolamine 1.3% patch
Trial: 26265197
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac 50 mg
Trial: 26265197
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium 50 mg
Trial: 26265197
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium plus ASA 325 mg
Trial: 26265197
Drug: Diclofenac patch
RxNorm normalized name: diclofenac Medicated Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac patch plus aspirin
Trial: 22366843
Drug: US-guided popliteal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided popliteal sciatic block (US-SPB) with 20 mL mepivacaine 1.5%
Trial: 22366843
Drug: Nerve stimulator-guided
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve stimulator-guided popliteal sciatic block (NS-SPB) with 20 mL mepivacaine 1.5%
Trial: 20060945
Drug: IC41 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC41 vaccine via subcutaneous (s.c.) or intradermal (i.d.) injections weekly (16 injections) or every other week (8 injections)
Trial: 20060945
Drug: IC41 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC41 vaccine with imiquimod
Trial: 20060945
Drug: IC41 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC41 vaccine via intradermal injections
Trial: 7607970
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) plus steroids
Trial: 623119
Drug: Aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide (6 g daily, three times a day)
Trial: 623119
Drug: Aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide capsules
Trial: 24352716
Drug: Bupropion (≤300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (≤300 mg/day)
Trial: 24352716
Drug: SSRIs (sertraline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (sertraline, paroxetine, or escitalopram)
Trial: 12074777
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 6g of L-arginine glutamate and 6 mg of yohimbine hydrochloride (AY)
Trial: 12074777
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of yohimbine hydrochloride (YP)
Trial: 6342395
Drug: Maternal magnesium
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal magnesium sulfate infusion
Trial: 31784875
Drug: Dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dimethyl fumarate (Tecfidera®), administered twice daily.
Trial: 30193081
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme replacement therapy (PERT) at maximum intake of 75,000 units per meal
Trial: 30193081
Drug: No PERT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No PERT treatment
Trial: 19647382
Drug: BZA 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZA 20 mg/CE 0.625 mg
Trial: 19647382
Drug: BZA 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZA 20 mg/CE 0.45 mg
Trial: 9345074
Drug: 9 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9 weeks of induction chemotherapy (vincristine, doxorubicin, cyclophosphamide, prednisone) followed by 24 weeks of continuation chemotherapy (mercaptopurine, methotrexate) without radiotherapy
Trial: 9345074
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of continuation chemotherapy after 9 weeks of induction chemotherapy
Trial: 9345074
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of continuation chemotherapy with radiotherapy after 9 weeks of induction chemotherapy
Trial: 9345074
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further therapy after 9 weeks of induction chemotherapy
Trial: 27484339
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion (0.1 μg/kg/min)
Trial: 27484339
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion (0.1 μg/kg/min) + Alfentanil (5 μg/kg 10 min before end of surgery)
Trial: 24762066
Drug: Anthracycline-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline-based chemotherapy followed by taxane therapy (Arm A)
Trial: 24762066
Drug: Taxane therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane therapy followed by anthracycline-based chemotherapy (Arm B)
Trial: 24762066
Drug: Chemotherapy sequence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy sequence (Arm A vs Arm B)
Trial: 20205108
Drug: sulfonylurea plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulfonylurea plus insulin
Trial: 20205108
Drug: routine diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: routine diet and sulfonylurea therapy
Trial: 18580739
Drug: Back school
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Back school program plus medication (n = 50)
Trial: 18580739
Drug: Medication only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication only (n = 52)
Trial: 10072410
Drug: Clozapine (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (6.25 to 50 mg per day)
Trial: 7793648
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg oral clonidine
Trial: 17294999
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg lidocaine
Trial: 27578062
Drug: Focused history
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused history in parallel choreography (concurrent with primary survey)
Trial: 20009130
Drug: Interferon-ribavirin treatment
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Interferon-ribavirin treatment
Trial: 15058117
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg/kg with rocuronium 0.6 mg/kg
Trial: 15058117
Drug: Thiopentone 4
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 4 mg/kg with rocuronium 0.6 mg/kg
Trial: 11302283
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose diuretic (indapamide sustained release 1.5mg daily) and additional ACE inhibitor (perindopril) therapy if required
Trial: 7979670
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (150 mg/day) for 7 days before operation
Trial: 29875020
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml normal saline (BN group)
Trial: 28319270
Drug: PFD patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFD patch
Trial: 26044495
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (multi-component antenatal vaccine promotion package)
Trial: 24350662
Drug: Oxybutynin patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin patch
Trial: 11834153
Drug: Intensive care
RxNorm normalized name: Rapifen Intensive Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive care therapy (ICT) in neurosurgical intensive care unit for the first 2 weeks after admission
Trial: 11834153
Drug: Conventional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional care therapy (CCT) in ordinary ward
Trial: 23796204
Drug: Cetuximab 250
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 250 mg/m²
Trial: 23796204
Drug: Cetuximab 250
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 250 mg/m² with paclitaxel 80 mg/m²
Trial: 17699280
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor
Trial: 9482764
Drug: OKG administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKG administration
Trial: 26683756
Drug: Exenatide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (5 mcg twice daily for 1 month, then 10 mcg twice daily for 2 months)
Trial: 23031322
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (IIT) guided by real-time continuous glucose monitoring (CGM), n = 63
Trial: 9239584
Drug: Etomidate (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.1 mg/kg)
Trial: 12399793
Drug: Midazolam (0.033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.033 mg/kg)
Trial: 18678568
Drug: Functional thumb
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional thumb orthosis used daily
Trial: 11054441
Drug: Paclitaxel 67.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 67.5 mg/m(2) and Carboplatin AUC 6 mg.min/mL
Trial: 11054441
Drug: Paclitaxel 81
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 81 mg/m(2) and Carboplatin AUC 6 mg/mL
Trial: 11054441
Drug: Paclitaxel 54.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 54.5 mg/m(2) to 94.5 mg/m(2)
Trial: 9085389
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment at points previously used for anti-smoking (test group, TG)
Trial: 9085389
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment at points assumed to have no effect for smoking cessation (control group, CG)
Trial: 3546149
Drug: Ofloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 200 mg b.i.d. by oral route
Trial: 3546149
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg b.i.d. by oral route
Trial: 23857248
Drug: Preladenant 10
RxNorm normalized name: Preladenant
DrugBank: Preladenant (DB11864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preladenant 10 mg BID for 5 days
Trial: 23857248
Drug: Preladenant 100
RxNorm normalized name: Preladenant
DrugBank: Preladenant (DB11864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preladenant 100 mg BID for 5 days
Trial: 23857248
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg on day 5
Trial: 18823310
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus strain GG (LGG) treatment
Trial: 18823310
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus strain GG (LGG) treatment in adults
Trial: 7577484
Drug: Pamidronate 90
RxNorm normalized name: pamidronate 90 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 90 mg
Trial: 12631257
Drug: Ibandronate 4
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 4 mg
Trial: 3814226
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg ketanserin
Trial: 6340300
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 ml saline)
Trial: 24096438
Drug: Dinoprostone (10-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone (10-mg intra-vaginal insert)
Trial: 12087347
Drug: Candesartan (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (single dose) or vitamin C (coinfusion)
Trial: 10689211
Drug: Once-daily cefdinir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily cefdinir 600 mg
Trial: 10689211
Drug: Twice-daily cefdinir
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily cefdinir 300 mg
Trial: 10689211
Drug: Twice-daily cefuroxime
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily cefuroxime axetil 250 mg
Trial: 18981463
Drug: ABT-510 20
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-510 20 mg once a day
Trial: 18981463
Drug: ABT-510 100
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-510 100 mg twice a day
Trial: 12207594
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) 2 g kg‐1, administered as an 8‐h infusion of 1 g kg‐1 daily for two consecutive days
Trial: 12207594
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment with IVIG (control group)
Trial: 2930745
Drug: Stamey endoscopic
RxNorm normalized name: Nelumbo nucifera stamen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stamey endoscopic bladder neck suspension
Trial: 1758315
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of seminar teaching and audiotapes
Trial: 1758315
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CAI and seminar teaching
Trial: 31894026
Drug: Pemetrexed combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed combined with platinum drugs and evidence‐based nursing mode
Trial: 31894026
Drug: Pemetrexed therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed therapy and routine nursing mode
Trial: 23665341
Drug: Adjuvanted vaccines
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted vaccines (30 μg, 60 μg, 90 μg)
Trial: 23665341
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg adjuvanted formulation
Trial: 9868662
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g once daily for 4 weeks
Trial: 791194
Drug: 225 mg
RxNorm normalized name: tyrosine 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 mg maprotiline per day
Trial: 791194
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg maprotiline per day (initial dosage for first 2 days)
Trial: 30377712
Drug: L-arginine (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (9 g/day) for 6 weeks
Trial: 28292574
Drug: Phospholipid liposomal
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phospholipid liposomal spray (Tears Again®)
Trial: 16877734
Drug: Docetaxel 60
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 60 mg/m2 (day 1) every 21 days for four cycles
Trial: 16877734
Drug: Vinorelbine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m2 (days 1 and 8) every 21 days for four cycles
Trial: 9013263
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 400 mg once a day orally for 4 weeks
Trial: 9013263
Drug: Pre-treatment state
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment state
Trial: 29759061
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with 20 ml 0.375% ropivacaine
Trial: 14675884
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg/day) + ACE inhibitor (lisinopril 5 mg/day)
Trial: 14675884
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor (lisinopril 5 mg/day) alone
Trial: 10982926
Drug: Bioefficient Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioefficient Therapy
Trial: 1294745
Drug: Ibuprofen (analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (analgesic and antiinflammatory doses)
Trial: 15504190
Drug: Dixyrazine 10
RxNorm normalized name: dixyrazine
DrugBank: Dixyrazine (DB13784)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dixyrazine 10 mg
Trial: 9760006
Drug: Policosanol 5
RxNorm normalized name: policosanol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 5 mg twice daily
Trial: 9760006
Drug: Policosanol 5
RxNorm normalized name: policosanol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 5 mg twice daily plus 125 mg aspirin
Trial: 9760006
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus 125 mg aspirin
Trial: 2455155
Drug: Metoprolol (MET),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (MET), 200 mg slow release (SR) q.d.
Trial: 28679410
Drug: Moxibustion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion treatment at CV8, CV12, LI4 and ST36, 30-min treatments twice a week for 8 weeks
Trial: 21635753
Drug: Staircase recruitment
RxNorm normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staircase recruitment manoeuvres (SRM) with decremental PEEP titration and targeted plateau pressure < 30 cm H2O
Trial: 7901254
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus heparin followed by aspirin plus warfarin
Trial: 14572753
Drug: Permixon (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permixon (160 mg bid for three months)
Trial: 14572753
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment for 3 weeks before surgery)
Trial: 10962896
Drug: Total mesorectal
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total mesorectal excision for middle and lower third rectal cancer
Trial: 10962896
Drug: Multivisceral resections
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivisceral resections for the treatment of advanced colorectal tumours
Trial: 9380919
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of propofol administered i.v. immediately after fetal extraction
Trial: 25362110
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg of aspirin
Trial: 31629656
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus goserelin (10.8 mg subcutaneous injection on the first day of irradiation and 3 months later)
Trial: 15201546
Drug: Amlodipine 5-10
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5-10 mg